Table 1.
Matched Baseline Characteristics
| Characteristic | Robotic vs Abdominal
|
Robotic vs Vaginal
|
||||
|---|---|---|---|---|---|---|
| Robotic (n=234) | Abdominal (n=234) | P Value | Robotic (n=212) | Vaginal (n=212) | P Value | |
| Age at surgery, mean (SD), y | 49.7 (12.1) | 49.1 (12.1) | .54 | 49.0 (11.6) | 46.7 (9.2) | .02 |
| Race, No. (%) | .17 | .004 | ||||
| White | 211 (90.2) | 201 (85.9) | 186 (87.7) | 187 (88.2) | ||
| Nonwhite | 10 (4.3) | 9 (3.8) | 16 (7.5) | 4 (1.9) | ||
| Unknown | 13 (5.6) | 24 (10.3) | 10 (4.7) | 21 (9.9) | ||
| Insurance status, No. (%) | … | .04 | ||||
| Commercial | 183 (78.2) | 186 (79.5) | 174 (82.1) | 188 (88.7) | ||
| Medicare | 35 (15.0) | 31 (13.2) | 22 (10.4) | 7 (3.3) | ||
| Other government | 14 (6.0) | 16 (6.8) | 13 (6.1) | 14 (6.6) | ||
| No insurance | 2 (0.9) | 1 (0.4) | 2 (0.9) | 2 (0.9) | ||
| Body mass index, mean (SD), kg/m2 | 30.4 (9.1) | 29.4 (7.4) | .60 | 30.3 (8.8) | 31.3 (22.7) | .39 |
| Pregnancies, mean (SD), No. | 2.0 (1.7) | 2.2 (2.1) | .72 | 2.0 (1.7) | 2.8 (1.5) | <.001 |
| Live births, mean (SD), No. | 1.6 (1.5) | 1.7 (1.7) | .74 | 1.5 (1.4) | 2.3 (1.2) | <.001 |
| Vaginal deliveries, mean (SD), No. | 1.1 (1.4) | 1.3 (1.7) | .14 | 1.1 (1.5) | 2.1 (1.2) | <.001 |
| Abdominal surgical procedures, mean (SD), No. | 1.5 (1.7) | 1.4 (1.4) | .87 | 1.4 (1.7) | 1.2 (1.3) | .55 |
| Comorbid conditions | ||||||
| Cardiovascular, No. (%) | 78 (33.3) | 77 (32.9) | .92 | 66 (31.1) | 47 (22.2) | .11 |
| Pulmonary, No. (%) | 36 (15.4) | 28 (12.0) | .28 | 34 (16.0) | 26 (12.3) | .54 |
| Gastrointestinal tract, No. (%) | 50 (21.4) | 41 (17.5) | .29 | 44 (20.8) | 46 (21.7) | .97 |
| Genitourinary tract, No. (%) | 0 (0) | 0 (0) | … | 2 (0.9) | 1 (0.5) | .85 |
| Endocrine, No. (%) | 68 (29.1) | 48 (20.5) | .03 | 53 (25.0) | 42 (19.8) | .44 |
| Hematologic, No. (%) | 47 (20.1) | 32 (13.7) | .06 | 43 (20.3) | 38 (17.9) | .83 |
| Social, No. (%) | 32 (13.7) | 41 (17.5) | .25 | 34 (16.0) | 34 (16.0) | >.99 |
| Other, No. (%) | 60 (25.6) | 56 (23.9) | .67 | 56 (26.4) | 46 (21.7) | .52 |
| Indication | ||||||
| Biopsy-proven hyperplasia, No. (%) | 15 (6.4) | 5 (2.1) | .02 | 12 (5.7) | 10 (4.7) | .66 |
| Abnormal uterine bleeding, No. (%) | 49 (20.9) | 27 (11.5) | .006 | 31 (14.6) | 87 (41.0) | <.001 |
| Gynecologic cancer, No. (%) | 48 (20.5) | 25 (10.7) | .003 | 38 (17.9) | 15 (7.1) | .001 |
| Pain, No. (%) | 31 (13.2) | 31 (13.2) | >.99 | 22 (10.4) | 16 (7.5) | .31 |
| Fibroids, No. (%) | 74 (31.6) | 70 (29.9) | .69 | 70 (33.0) | 52 (24.5) | .05 |
| Adnexal mass, No. (%) | 14 (6.0) | 53 (22.6) | <.001 | 12 (5.7) | 13 (6.1) | .84 |
| Other indication, No. (%) | 29 (12.4) | 24 (10.3) | .47 | 27 (12.7) | 20 (9.4) | .28 |